The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
In addition to cutting the risk for fatty liver disease, research presented at the Research Society on Alcoholism conference confirmed two distinct approaches that can help those battling alcoholism.
Continue reading »Learn about the discovery made by St. Louis researchers that will expand the liver donor pool for HCV patients, and find out if Hepatitis C serology affects post-liver transplant survival rate.
Continue reading »Although currently recovering from combination therapy's side effects, the well-respected vocalist Natalie Cole may have conquered the Hepatitis C virus.
Continue reading »Pittsburgh researchers have found an enzyme known to participate in fat production is elevated in those with Hepatitis C. Further exploration of this enzyme could help physicians better predict which HCV patients are at risk of developing fatty liver disease.
Continue reading »Reducing the dosing schedule in half, Anadys Pharmaceuticals continues its investigation of ANA773, a Toll-Like Receptor-7 agonist prodrug. Approaching the Hepatitis C virus differently from most other contenders, Phase I clinical trials evaluating the safety, tolerability and viral-load decline associated with ANA773 are about to begin in the Netherlands.
Continue reading »Scientists have found a popular street drug worsens Hepatitis C infection in two worrisome ways.
Continue reading »Since only about half of those on combination therapy beat Hepatitis C, the remaining people must strive to prevent their liver disease from progressing. Thus far, a liver wellness approach is a safer, more effective way to remain healthy compared to long-term interferon therapy.
Continue reading »A Phase 3 trial evaluating ZADAXIN® (thymalfasin) as a potential third component for Hepatitis C traditional combination therapy has just been completed. Although the data is currently being analyzed and won't be available until later in the year, the lead investigator anticipates good news for previous non-responders.
Continue reading »The Taiwan-based biopharmaceutical company PharmaEssentia Corp. is testing P1101, its third-generation PEG-interferon-alpha drug candidate. Because it is a longer-lasting, purer interferon that is less costly to produce, P1101 could enhance the treatment options for Hepatitis C and B.
Continue reading »While pharmaceutical companies are racing to find safer, more effective treatments for viral Hepatitis C and B, physicists from Arizona have a unique perspective on accomplishing the same goal. Learn how these scientists believe the virus could be rendered harmless with this non-traditional, non-invasive procedure.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
